Myra Langendonk
Overview
Explore the profile of Myra Langendonk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langendonk M, Smit N, Plattel W, Diepstra A, van Meerten T, Visser L
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430230
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities...
2.
Langendonk M, de Jong M, Smit N, Seiler J, Reitsma B, Ammatuna E, et al.
Blood Cancer J
. 2022 Mar;
12(3):36.
PMID: 35256592
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Despite the proven efficacy of combined immunochemotherapy (R-CHOP) in the majority of patients, ~40% of DLBCL patients do not...
3.
de Jong M, Langendonk M, Reitsma B, Herbers P, Lodewijk M, Nijland M, et al.
Ther Adv Hematol
. 2020 Feb;
11:2040620719898373.
PMID: 32010435
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, characterized by high levels of genomic instability and the activation of DNA damage repair pathways. We previously found high expression...
4.
de Jong M, Langendonk M, Reitsma B, Nijland M, van den Berg A, Ammatuna E, et al.
Int J Mol Sci
. 2019 Dec;
20(23).
PMID: 31801186
Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy with cyclophosphamide, vincristine, doxorubicin, prednisolone, and...
5.
de Jong M, Langendonk M, Reitsma B, Herbers P, Nijland M, Huls G, et al.
Cancers (Basel)
. 2019 Nov;
11(11).
PMID: 31703356
Genomically unstable cancers are dependent on specific cell cycle checkpoints to maintain viability and prevent apoptosis. The cell cycle checkpoint protein WEE1 is highly expressed in genomically unstable cancers, including...
6.
Wu R, Nijland M, Rutgers B, Veenstra R, Langendonk M, van der Meeren L, et al.
PLoS One
. 2016 Jan;
11(1):e0146624.
PMID: 26752561
Follicular lymphoma and diffuse large B cell lymphomas comprise the main entities of adult B cell malignancies. Although multiple disease driving gene aberrations have been identified by gene expression and...